What Is Driving Global Convalescent Plasma Therapy Market Growth in 2025: The Role of Efficacy And Safety Propel The Convalescent Plasma Therapy Market

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Convalescent Plasma Therapy Market Size Growth Forecast: What to Expect by 2025?
The convalescent plasma therapy market has observed substantial expansion lately, projected to increase from a valuation of $0.05 billion in the year 2024 to $0.06 billion by 2025, reflecting an 11.1% compound annual growth rate; this upward trajectory during the past period is largely influenced by occurrences of pandemics and infectious disease epidemics, ongoing investigations into immunotherapy, the granting of emergency use authorizations, the supply of eligible patients, and rising recognition among both healthcare providers and the general public.

How Will the Convalescent Plasma Therapy Market Size Evolve and Grow by 2029?
Anticipation surrounds the convalescent plasma therapy sector, projecting a swift expansion over the approaching years, with its market valuation set to reach $0.09 billion by 2029, driven by a compound annual growth rate (CAGR) of 13.6%; this upward trajectory is fueled by the emergence of novel pathogens, advancements in immunotherapy creation, the establishment of robust regulatory structures, enhanced worldwide readiness, and proactive public health campaigns, while key shifts shaping this period involve the standardization of plasma gathering and handling protocols, a focus on specific plasma elements for customized therapeutic applications, the advent of bespoke patient treatments, the integration of remote patient observation alongside telemedicine, and ongoing investigations into the long-term outcomes associated with this therapy.

View the full report here:
https://www.thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report

What Drivers Are Propelling the Growth of Convalescent Plasma Therapy Market Forward?
The market expansion throughout the projection timeframe is anticipated to be propelled by the elevated levels of effectiveness and security demonstrated by Convalescent Plasma Therapy (CPT) in patients afflicted with COVID-19 during clinical assessments. Historically, the transfusion of convalescent plasma has garnered significant attention as a potential treatment modality for various past outbreaks of contagious diseases, including SARS-1, the Middle East Respiratory Syndrome (MERS), and the 2009 H1N1 influenza. Supporting evidence emerged in June 2022 when findings from a Houston Methodist hospital investigation into the safety and efficacy profile of COVID-19 convalescent plasma treatment confirmed its safety, noting an absence of adverse incidents, and highlighted its effectiveness with a 76 percent recovery figure. Further reinforcing this therapeutic avenue, a May 2020 publication in the Journal of Medical Virology asserted that employing convalescent plasma therapy could lead to a decrease in mortality among severely ill individuals, produce favorable impacts on observable clinical manifestations, and correspond with a rise in the levels of neutralizing antibodies alongside the clearance of SARS-CoV-2 RNA, ultimately fueling the progression of the worldwide convalescent plasma therapy sector due to its proven safety and efficacy in COVID-19 cases.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3233&type=smp

Which Emerging Trends Are Transforming the Convalescent Plasma Therapy Market in 2025?
Opportunities are emerging within the convalescent plasma therapy market due to advancements in antibody-based immunotherapy treatments for COVID-19. This therapy leverages the immune globulins generated by recovered donors to bolster the recipient's defenses against the coronavirus. Various firms are actively launching trials, forming partnerships, and allocating funds toward antibody treatments for COVID-19. Notably, in August 2023, Regeneron Pharmaceuticals Inc., a biotechnology entity located in the US, established a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to facilitate the progression of next-generation COVID-19 monoclonal antibody treatments through clinical trials, manufacturing scaled for clinical use, and the acquisition of regulatory approval for preventing SARS-CoV-2 infection. This joint effort is integrated into Project NextGen, an initiative spearheaded by the U.S. Department of Health and Human Services (HHS) aimed at cultivating a robust supply of contemporary COVID-19 vaccines and treatments. Within this framework, Regeneron is tasked with independently creating and proposing an antibody candidate, which will subsequently be evaluated by both BARDA and Regeneron to determine its suitability for further investigation, production, and regulatory submission. Given that convalescent plasma therapy fundamentally relies on antibodies, the heightened concentration on antibody-centric approaches for COVID-19 treatment is anticipated to fuel expansion within the market.

What Are the Key Segments in the Convalescent Plasma Therapy Market?
The convalescent plasma therapymarket covered in this report is segmented -

1) By Antibody type: IgM; IgG; IgA
2) By Application: Prophylaxis; Treatment
3) By End-Users: Hospitals And Clinics; Laboratories And Research institutes

Subsegments:
1) By IgM: Early-Stage Infection Plasma; Acute Phase Plasma; Other IgM-Based Plasma Products
2) By IgG: High Titer IgG Plasma; Standard IgG Plasma; Other IgG-Based Plasma Products
3) By IgA: Plasma Rich In IgA; Specific IgA Antibody Plasma; Other IgA-Based Plasma Products

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3233&type=smp

Who Are the Key Players Shaping the Convalescent Plasma Therapy Market's Competitive Landscape?
Major companies operating in the convalescent plasma therapy market include Bio Farma, Hilton Pharma Ltd., Biotest AG, BPL Ltd., LFB SA, Octapharma AG, CSL Behring LLC, Takeda Pharmaceutical Company Ltd., Orthosera Kft., ADMA Biologics Inc., GC Biopharma Corp, Grifols S.A, Sanquin Plasma Products B.V., America's Blood Centers, Blood Centers of America Inc., Anthem Inc., Laboratory Corporation of America Holdings, Cerus Corporation, Emergent BioSolutions Inc., Kedrion Biopharma Inc., New York Blood Center, Blood Systems Inc., OneBlood Inc., Gulf Coast Regional Blood Center, Bloodworks Northwest, Blood Assurance Inc., New York Blood Center Inc., Honolulu Blood-Plasma Bank, Community Blood Center, LifeStream Blood Bank

What Geographic Markets Are Powering Growth in the Convalescent Plasma Therapy Market?
North America was the largest region in the convalescent plasma therapy market in 2024. Western Europe was the second largest region in the convalescent plasma therapy market. The regions covered in the convalescent plasma therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3233

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.